Holt S, Howden C W
Division of Digestive Diseases and Nutrition, University of South Carolina School of Medicine, Columbia.
Dig Dis Sci. 1991 Apr;36(4):385-93. doi: 10.1007/BF01298864.
Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K(+)-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the "proton pump," catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.
奥美拉唑是一种取代苯并咪唑，是H+/K(+)-ATP酶的特异性抑制剂，该酶存在于壁细胞的分泌表面。这种酶，即“质子泵”，催化胃酸分泌的最后一步。奥美拉唑是一种强效胃酸分泌抑制剂。在撰写本文时，奥美拉唑在美国已获许可用于治疗重度胃食管反流病（GERD）以及对现有药物治疗无反应的GERD，还用于治疗卓-艾综合征和其他胃酸分泌过多状态。最近，美国食品药品监督管理局（FDA）咨询委员会已建议批准其作为十二指肠溃疡病的一线治疗药物。
